Long-term outcome of patients with palindromic rheumatism treated with methotrexate.

Arezoo GhassembaglouKamal EsalatmaneshLeyla GadakchiFarnaz NourmohammadiAlireza Khabbazi

Published in: International journal of rheumatic diseases (2022)

The present study, demonstrated the efficacy of MTX in controlling PR in seropositive and seronegative patients over a median of 43 months of treatment.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
high dose
low dose
patient reported outcomes